Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Status:
Terminated
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of different doses of epoetin
alfa for treating anemia in patients who have cancer; or patients who no longer have any
signs of cancer, but remain anemic as a result of their treatment. These patients should not
be currently receiving chemotherapy or radiotherapy. A subject's participation in the study
will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or
placebo. Their hemoglobin will be tested every week.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.